These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22989990)

  • 1. CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies.
    Haryadi R; Zhang P; Chan KF; Song Z
    Bioengineered; 2013; 4(2):90-4. PubMed ID: 22989990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant.
    Zhang P; Haryadi R; Chan KF; Teo G; Goh J; Pereira NA; Feng H; Song Z
    Glycobiology; 2012 Jul; 22(7):897-911. PubMed ID: 22492235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies.
    Chan KF; Shahreel W; Wan C; Teo G; Hayati N; Tay SJ; Tong WH; Yang Y; Rudd PM; Zhang P; Song Z
    Biotechnol J; 2016 Mar; 11(3):399-414. PubMed ID: 26471004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
    Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
    Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing recombinant glycoprotein sialylation through CMP-sialic acid transporter over expression in Chinese hamster ovary cells.
    Wong NS; Yap MG; Wang DI
    Biotechnol Bioeng; 2006 Apr; 93(5):1005-16. PubMed ID: 16432895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
    Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
    Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.
    Roy G; Martin T; Barnes A; Wang J; Jimenez RB; Rice M; Li L; Feng H; Zhang S; Chaerkady R; Wu H; Marelli M; Hatton D; Zhu J; Bowen MA
    MAbs; 2018 Apr; 10(3):416-430. PubMed ID: 29400603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of FX
    Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
    Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid residues important for CMP-sialic acid recognition by the CMP-sialic acid transporter: analysis of the substrate specificity of UDP-galactose/CMP-sialic acid transporter chimeras.
    Takeshima-Futagami T; Sakaguchi M; Uehara E; Aoki K; Ishida N; Sanai Y; Sugahara Y; Kawakita M
    Glycobiology; 2012 Dec; 22(12):1731-40. PubMed ID: 22833315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies.
    Wong AW; Baginski TK; Reilly DE
    Biotechnol Bioeng; 2010 Aug; 106(5):751-63. PubMed ID: 20564613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies.
    Malphettes L; Freyvert Y; Chang J; Liu PQ; Chan E; Miller JC; Zhou Z; Nguyen T; Tsai C; Snowden AW; Collingwood TN; Gregory PD; Cost GJ
    Biotechnol Bioeng; 2010 Aug; 106(5):774-83. PubMed ID: 20564614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evidence for GDP-fucose transport in the absence of transporter SLC35C1 and putative transporter SLC35C2.
    Lu L; Varshney S; Yuan Y; Wei HX; Tanwar A; Sundaram S; Nauman M; Haltiwanger RS; Stanley P
    J Biol Chem; 2023 Dec; 299(12):105406. PubMed ID: 38270391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
    Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slc35c2 promotes Notch1 fucosylation and is required for optimal Notch signaling in mammalian cells.
    Lu L; Hou X; Shi S; Körner C; Stanley P
    J Biol Chem; 2010 Nov; 285(46):36245-54. PubMed ID: 20837470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
    von Horsten HH; Ogorek C; Blanchard V; Demmler C; Giese C; Winkler K; Kaup M; Berger M; Jordan I; Sandig V
    Glycobiology; 2010 Dec; 20(12):1607-18. PubMed ID: 20639190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encephalopathy caused by novel mutations in the CMP-sialic acid transporter, SLC35A1.
    Ng BG; Asteggiano CG; Kircher M; Buckingham KJ; Raymond K; Nickerson DA; Shendure J; Bamshad MJ; ; Ensslen M; Freeze HH
    Am J Med Genet A; 2017 Nov; 173(11):2906-2911. PubMed ID: 28856833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering host cell lines to reduce terminal sialylation of secreted antibodies.
    Naso MF; Tam SH; Scallon BJ; Raju TS
    MAbs; 2010; 2(5):519-27. PubMed ID: 20716959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic engineering of CHO cells for viral resistance to minute virus of mice.
    Mascarenhas JX; Korokhov N; Burger L; Kassim A; Tuter J; Miller D; Borgschulte T; George HJ; Chang A; Pintel DJ; Onions D; Kayser KJ
    Biotechnol Bioeng; 2017 Mar; 114(3):576-588. PubMed ID: 27642072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter.
    Martinez-Duncker I; Dupré T; Piller V; Piller F; Candelier JJ; Trichet C; Tchernia G; Oriol R; Mollicone R
    Blood; 2005 Apr; 105(7):2671-6. PubMed ID: 15576474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
    J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.